Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41384083
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Eur Heart J Case Rep
2025[Dec]; 9
(12
): ytaf405
PMID41384083
show ga
BACKGROUND: Thrombotic thrombocytopaenic purpura (TTP) is a rare and potentially
life-threatening form of thrombotic microangiopathy, characterized by
thrombocytopaenia, haemolytic anaemia, neurological disturbances, and organ
dysfunction. Clopidogrel is widely used in patients undergoing percutaneous
coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) due to
its antiplatelet effects. However, the occurrence of TTP as an adverse effect of
clopidogrel, though rare, requires greater awareness within the medical
community. CASE SUMMARY: We present a case of a female patient with symptoms of
thrombocytopaenia, haemolytic anaemia, neurological disturbances, and renal
impairment following clopidogrel administration after PCI for STEMI. The patient
was diagnosed with TTP, which was confirmed by the resolving of the symptoms
after the withdrawal of clopidogrel. DISCUSSION: This case underscores the
importance of awareness and prompt management of TTP as a serious adverse effect
of clopidogrel. The main takeaway is the critical need for clinicians to
recognize and address this rare complication to improve patient outcomes.
Documenting such cases is essential to raise awareness among healthcare providers
about this potentially life-threatening condition.
free
free
free
